NEW YORK, July 30, 2018 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the important August 13, 2018 lead plaintiff deadline in the shareholder class action lawsuit against Akers Biosciences, Inc. (“Akers” or the “Company”) ( AKER). The lawsuit seeks to recover damages on behalf of those who purchased the securities of Akers between May 15, 2017 and June 5, 2018, both dates inclusive (the “Class Period”).
To join the Akers class action, and/or to discuss your legal rights and options, please visit Akers Biosciences Shareholder Class Action Lawsuit or contact Daniel Sadeh toll free at (877) 779-1414 or [email protected].
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Akers was improperly recognizing revenue for the fiscal year ended December 31, 2017; (2) Akers had downplayed weaknesses in its internal controls over financial reporting and failed to disclose the true extent of those weaknesses; and (3) as a result, Defendants’ statements about Akers’ business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
On May 21, 2018, during aftermarket hours, Akers revealed that its ongoing review of the characterization of certain revenue recognition items for the quarter ended March 31, 2018 “now includes certain transactions in previous quarters.” As a result, Akers stated that “the Company is unable to file its 10-Q for the quarter ended March 31, 2018 today.”
On this news, Akers’ stock fell $0.058 per share, or over 8%, from its previous closing price to close at $0.599 per share on May 22, 2018, damaging investors.
On May 29, 2018, Akers revealed “that Raymond F. Akers Jr., Ph.D has resigned as a director of the Company with immediate effect.”
On this news, Akers’ stock fell $0.263 per share, or over 44%, over two consecutive trading days to close at $0.326 per share on May 30, 2018, damaging investors.
Then, on June 1, 2018, Akers filed a Form 8-K with the SEC attaching a letter from Raymond Akers to the Company. In the letter, Mr. Akers stated that “I have resigned from the Board of Directors due to significant differences regarding the policies and practices of the Board of Directors, accounting and business practices of Management, and new Counsel. I believe this to be in the best interests of the Company, shareholders, and me.”
If you wish to serve as lead plaintiff, you must move the Court no later than August 13, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
To join the Akers class action, and/or to discuss your legal rights and options, please visit https://www.bernlieb.com/cases/akers-biosciences-inc-aker-lawsuit-class-action-fraud-stock-67/ or contact Daniel Sadeh toll free at (877) 779-1414 or [email protected].
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for ten consecutive years.
ATTORNEY ADVERTISING. © 2018 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information
Daniel Sadeh
Bernstein Liebhard LLP
http://www.bernlieb.com
(877) 779-1414
[email protected]
